Literature DB >> 4972183

The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

I Gigli, S Ruddy, K F Austen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4972183

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  51 in total

1.  Purificaiton and characterization of mouse serum protein with specific binding affinity for C4 (Ss protein).

Authors:  A Ferreira; M Takahashi; V Nussenzweig
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

2.  Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge.

Authors:  S I Wasserman; N A Soter; D M Center; K F Austen
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Differences between plasma and serum complement in patients with chronic liver disease.

Authors:  S Inai; H Kitamura; T Fujita; J Kojima; K Nagaki
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

4.  Immune complexes in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

5.  C1 inactivator inhibition by plasmin.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

6.  Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and skynovial membrane cells from patients with rheumatoid arthritis.

Authors:  C de Ceulaer; S Papazoglou; K Whaley
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

7.  In vitro activation of C1s in plasma of patients with hereditary angioneurotic oedema.

Authors:  S Shafiasghar; R H Cormane; K W Pondman
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

8.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

9.  Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M M Frank
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.